|
End-of-day quote
Taipei Exchange
2026-08-19
|
5-day change | 1st Jan Change | ||
| 939.00 TWD | +4.92% |
|
0.00% | +136.52% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 77.77B 2.46B 2.12B 1.98B 1.81B 3.41B 235B 3.42B 23.54B 9.19B 118B 9.22B 9.02B 393B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 61.5B 1.94B 1.67B 1.57B 1.43B 2.7B 186B 2.71B 18.62B 7.26B 93.71B 7.29B 7.13B 311B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +4.92% | ||
| Current month | +37.89% | ||
| 1 month | +60.79% | ||
| 3 months | +149.40% | ||
| 6 months | +129.87% | ||
| Current year | +136.52% |
| 1 month | 547 |  | 969 |
| Current year | 331 | | 969 |
| 1 year | 149 | | 969 |
| 3 years | 70 | | 969 |
| 5 years | 70 | | 969 |
| 10 years | 27 | | 969 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 2016-05-31 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 2022-07-24 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 2016-10-12 |
Cheng Chi Wang
BRD | Director/Board Member | - | 2024-06-26 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 2018-09-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.92% | 0.00% | +517.76% | +630.74% | 2.46B | |
| -0.13% | -6.44% | +60.34% | +112.06% | 1,047B | |
| +0.85% | -0.81% | +51.29% | +63.13% | 646B | |
| -1.03% | -3.58% | +21.43% | +73.10% | 451B | |
| -1.46% | -4.50% | +37.80% | +37.41% | 355B | |
| -0.72% | -2.89% | +22.32% | +36.62% | 291B | |
| -1.19% | -2.21% | +1.53% | +10.79% | 252B | |
| -1.05% | -1.57% | +50.30% | +66.55% | 234B | |
| +0.08% | -1.78% | -17.64% | -54.36% | 203B | |
| -2.14% | -0.30% | +28.95% | +86.27% | 181B | |
| Average | -0.19% | -1.75% | +77.41% | +106.23% | 366.17B | |
| Weighted average by Cap. | -0.46% | -3.45% | +38.49% | +65.38% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -23.5M -20.25M -18.99M -17.33M -32.66M -2.25B -32.76M -225M -87.9M -1.13B -88.24M -86.32M -3.76B | -1.36B -43.04M -37.09M -34.77M -31.74M -59.8M -4.11B -59.99M -413M -161M -2.08B -162M -158M -6.88B |
| Net Debt | -5.17B -163M -141M -132M -121M -227M -15.62B -228M -1.57B -611M -7.88B -613M -600M -26.14B | -16.27B -514M -443M -415M -379M -714M -49.11B -716M -4.92B -1.92B -24.79B -1.93B -1.89B -82.19B |
Employees
-
Sector
Pharmaceuticals
Calendar
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
